权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bronchoscope-guided microwave ablation of early-stage lung tumors

支气管镜引导下早期肺部肿瘤微波消融

基本信息

批准号：
10312004
负责人：
Punit Prakash
金额：
$ 20.09万
依托单位：
KANSAS STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-01-15 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10312004
关键词：
Ablation Address Animal Model Animals British Columbia Bronchoscopes Bronchoscopy Clinical Clinical Research Computer Models Coupled Data Deposition Development Devices Ensure Environment Evaluation Feedback Goals Growth Heating Human Incineration Industrialization Industry Interstitial Lung Diseases Kansas Kidney Liver Lung Lung Neoplasms Lung diseases Machine Learning Malignant neoplasm of lung Medical Modality Monitor Nodule Non-Small-Cell Lung Carcinoma Nonionizing Radiation Operative Surgical Procedures Organ Outcome Patients Pattern Physicians Pilot Projects Pneumothorax Positioning Attribute Procedures Pulmonary Emphysema Radiation therapy Research Research Support Risk Safety Survival Rate System Techniques Technology Thermal Ablation Therapy Time Tissues Toxic effect Translating Translational Research Translations Treatment Efficacy Treatment outcome Universities Unresectable Work animal data base computerized cost cost effective cost effective treatment design effective therapy efficacious treatment efficacy outcomes electric impedance experience experimental study first-in-human flexibility image guided improved in vivo innovation lung preservation microwave ablation microwave electromagnetic radiation minimal risk minimally invasive novel optimal treatments pre-clinical pulmonary function real time monitoring safety and feasibility simulation tool treatment planning tumor tumor ablation virtual

项目摘要

PROJECT SUMMARY In this Industry-Academic partnership R01 research plan, we propose the development, optimization, and pilot first-in-human evaluation of a bronchoscope-guided microwave ablation (MWA) system for rapid and conformal thermal ablation of early stage pulmonary tumors. Minimally-invasive, image- guided MWA is a cost-effective treatment for thermal destruction of unresectable tumors in the liver, lung, kidney, and other organs. Current MWA technology for pulmonary tumors is limited to a percutaneous approach, which precludes treatment of central tumors and has a high associated risk of pneumothorax. Furthermore, limited intra-procedural feedback and lack of guidance and treatment planning tools places a substantial burden on the physician to precisely position applicators and ensure adequate ablation of the target, while limiting damage to non-targets. Virtual bronchoscopy and navigation, pioneered by Broncus Medical (industrial partner), affords accurate, minimally-invasive access to early-stage pulmonary tumors, with minimal risk of pneumothorax, compared to a percutaneous approach. The team at Kansas State University (academic partner) will develop optimized flexible microwave applicators for delivering localized thermal ablation to pulmonary tumors via a bronchoscopic approach. The proposed MWA devices include antennas with directional control of microwave power deposition for precise ablation of small targets, and will be extensively evaluated with computational models and experimentally, on the benchtop, and in an in vivo animal model. Transient changes in antenna impedance matching will be exploited as a feedback parameter for assessing ablation progress. A machine-learning based treatment planning and guidance platform will be developed and integrated with Broncus’ Archimedes planning and virtual bronchoscopy platform to guide the selection of optimal treatment parameters. The integrated system will be translated for first-in- human studies to evaluate the feasibility and safety of bronchoscopically delivering MWA for targeting pulmonary tumors (subaward with University of British Columbia, through Broncus Medical). The central hypothesis of this research is that a bronchoscopic MWA system integrating: (1) applicators with directional control of ablation profiles; (2) impedance-based intra-procedural feedback; and (3) bronchoscopic guidance and treatment planning tools, will afford the safe and effective treatment of localized early-stage pulmonary tumors. The proposed research will lead to the development of an integrated system for bronchoscopic ablation of pulmonary tumors, and its pilot feasibility assessment in human patients. If successful, this work will considerably expand the range of patients with lung tumors that can be treated with a cost-effective, minimally-invasive approach.

项目总结在这次产学合作R01研究计划中，我们提出了开发、优化、以及对支气管镜引导的微波消融(MWA)系统进行首次人体评估早期肺肿瘤的快速适形热消融。微创，成像- 导引下的MWA是一种对不能切除的肝脏肿瘤进行热销毁的经济有效的治疗方法，肺、肾和其他器官。目前治疗肺部肿瘤的MWA技术仅限于经皮途径，这排除了中心性肿瘤的治疗，并有很高的相关风险气胸。此外，程序内反馈有限，缺乏指导和治疗计划工具给医生带来了很大的负担，他们需要精确定位涂抹器并确保对目标进行充分的烧蚀，同时限制对非目标的伤害。虚拟支气管镜检查和由Broncus Medical(工业合作伙伴)首创的导航系统为用户提供准确、微创的获得早期肺部肿瘤的机会，气胸风险最小，与经皮穿刺法。堪萨斯州立大学的团队(学术合作伙伴)将开发优化的柔性微波辐射器用于肺肿瘤的局部热消融通过支气管镜检查。建议的MWA设备包括具有方向控制的天线微波功率沉积用于精确烧蚀小目标，并将得到广泛的评估在计算模型和实验上，在桌面上，在活体动物模型中。瞬变天线阻抗匹配的变化将被用作评估的反馈参数消融进度。将建立一个基于机器学习的治疗规划和指导平台与Broncus的阿基米德规划和虚拟支气管镜平台开发和集成，以指导选择最佳处理参数。集成系统将被翻译为First in-in- 评价支气管镜下靶向注射MWA的可行性和安全性的人体研究肺部肿瘤(不列颠哥伦比亚大学授予的子奖，通过Broncus Medical获得)。这个这项研究的中心假设是，支气管镜MWA系统集成：(1)涂抹器和消融轮廓的定向控制；(2)基于阻抗的术中反馈；以及(3) 支气管镜指导和治疗计划工具，将提供安全有效的治疗局限性早期肺部肿瘤。拟议的研究将导致开发一种肺肿瘤支气管镜消融综合系统及其试点可行性评价在人类病人身上。如果成功，这项工作将极大地扩大肺部疾病患者的范围。可以用一种经济高效、微创方法治疗的肿瘤。